Inhibikase director forfeits 19,089 IKT shares

Inhibikase Therapeutics director Amit Munshi reported a forfeiture of previously issued shares.

Rhea-AI Filing Summary

Inhibikase Therapeutics director Amit Munshi reported a forfeiture of previously issued shares. On February 21, 2026, 19,089 shares of common stock were returned to the company after a milestone related to the February 21, 2025 CorHepta Pharmaceuticals acquisition was not achieved. Munshi received no cash or other consideration for this disposition to the issuer.

Following the forfeiture, he holds 38,176 shares of common stock directly and 365,000 shares indirectly through the Amit Munshi Revocable Trust.

Insider Trade Summary

Disposition: 19,089 shares

Disposition 2 txns

Insider Munshi Amit

Role Director

Type	Security	Shares	Price	Value
Disposition	Common Stock	19,089	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 38,176 shares (Direct); Common Stock — 365,000 shares (Indirect, By Amit Munshi Revocable Trust)

Footnotes (1)

1. F1. As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

FAQ

What insider transaction did Inhibikase Therapeutics (IKT) disclose for Amit Munshi?

Inhibikase Therapeutics disclosed that director Amit Munshi forfeited 19,089 shares of common stock back to the company. The forfeiture occurred when a milestone tied to the CorHepta Pharmaceuticals acquisition was not met by February 21, 2026, and no consideration was received.

Why were 19,089 IKT shares forfeited by Amit Munshi?

The 19,089 shares were subject to forfeiture if a specified milestone was not achieved by the first anniversary of the February 21, 2025 CorHepta acquisition closing. That milestone was not met by February 21, 2026, triggering automatic forfeiture of all 19,089 shares to the issuer.

Did Amit Munshi receive any payment for the forfeited Inhibikase Therapeutics shares?

No payment was received for the forfeited shares. The filing states Munshi received no consideration from Inhibikase Therapeutics when the 19,089 shares were forfeited on February 21, 2026, after the transaction milestone condition from the CorHepta acquisition was not satisfied.

How many Inhibikase Therapeutics shares does Amit Munshi hold after the forfeiture?

After the forfeiture, Munshi holds 38,176 Inhibikase Therapeutics common shares directly. He also has indirect ownership of 365,000 common shares through the Amit Munshi Revocable Trust, as reported in the Form 4 insider filing for February 21, 2026.

What is the role of the Amit Munshi Revocable Trust in IKT share ownership?

The Amit Munshi Revocable Trust holds 365,000 Inhibikase Therapeutics common shares indirectly for Munshi. The Form 4 identifies this trust as the nature of indirect ownership, distinguishing these holdings from his 38,176 directly owned shares after the milestone-based forfeiture.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 08:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Munshi Amit

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/21/2026		D		19,089(1)	D	$0	38,176(1)	D
Common Stock								365,000	I	By Amit Munshi Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

	/s/ Mark Iwicki, attorney-in-fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.